Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Stem Cell Educator Therapy Treat the Viral Inflammation in COVID-19

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04299152
Recruitment Status : Not yet recruiting
First Posted : March 6, 2020
Last Update Posted : April 14, 2020
Sponsor:
Information provided by (Responsible Party):
Tianhe Stem Cell Biotechnologies Inc.

Brief Summary:
Currently, the growing epidemic of a new coronavirus infectious disease (Covid-19) is wreaking havoc worldwide, which is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 is a RNA virus that display high similarity in both genomic and proteomic profiling with SARS-CoV that first emerged in humans in 2003 in China. Therefore, preventing and controlling the pandemic occurrences are extremely urgent as a global top priority. Due to the lack of effective antiviral drugs, patients may be treated by only addressing their symptoms such as reducing fever. Clinical autopsies from SARS-CoV-infected patients demonstrated that there were major pathological changes in the lungs, immune organs, and small systemic blood vessels with vasculitis. However, the detection of SARS-CoV were primarily found in the lung and trachea/bronchus, but was undetectable in spleen, lymph nodes, bone marrow, heart and aorta, highlighting the overreaction of immune responses induced by viral infection were really harmful, resulting in the pathogenesis of lungs, immune organs, and small systemic blood vessels. To this respect, immune modulation strategy may be potentially beneficial to enhance anti-viral immunity and efficiently reduce the viral load, improve clinical outcomes, expedite the patient recovery, and decline the rate of mortality in patients after being infected with SARS-CoV-2. Tianhe Stem Cell Biotechnologies Inc. has developed a novel globally-patented Stem Cell Educator (SCE) technology designed to reverse the autoimmune response in Type 1 diabetes (T1D), Alopecia Areata (AA) and other autoimmune diseases. SCE therapy uses human multipotent cord blood stem cells (CB-SC) from human cord blood. Their properties distinguish CB-SC from other known stem cell types, including mesenchymal stem cells (MSC) and hematopoietic stem cells (HSC). Several clinical studies show that SCE therapy functions via CB-SC induction of immune tolerance in autoimmune T cells and restore immune balance and homeostasis in patients with T1D, AA and other inflammation-associated diseases. To correct the overreaction of overreaction of immune responses, the investigators plan to treat SARS-CoV-2 patients with Stem Cell Educator therapy.

Condition or disease Intervention/treatment Phase
Severe Acute Respiratory Syndrome (SARS) Pneumonia Combination Product: Stem Cell Educator-Treated Mononuclear Cells Apheresis Phase 2

Detailed Description:
This is a prospective, two-arm, partially masked, single center clinical study to assess the safety, feasibility, and efficacy of SCE therapy for the treatment of patients with SARS-CoV-2 infection. Patients will be evaluated by the study principal investigator or co-investigators. Informed consent will be obtained at the initial screening visit. Subjects who meet all criteria will be scheduled for treatment. All enrolled subjects will receive one treatment with the SCE therapy consisting of a single session of mononuclear cells (MNC) collection by apheresis of blood. The MNC product will be treated with the SCE, and followed by an infusion intravenously back to the patient. The SCE-treated subjects will be evaluated according to the schedules of follow-up studies within 4 weeks.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: This is a prospective, two-arm, partially masked, single center clinical study to assess the safety, feasibility, and efficacy of SCE therapy for the treatment of patients with SARS-CoV-2.
Masking: Single (Care Provider)
Primary Purpose: Treatment
Official Title: Clinical Application of Stem Cell Educator Therapy for the Treatment of Viral Inflammation Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Estimated Study Start Date : May 10, 2020
Estimated Primary Completion Date : October 9, 2020
Estimated Study Completion Date : November 10, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Stem Cell Educator therapy treat patients with SARS-CoV-2
SCE therapy circulates a patient's blood through a blood cell separator, briefly cocultures the patient's immune cells with adherent CB-SC in vitro, and returns the "educated" autologous immune cells to the patient's circulation.
Combination Product: Stem Cell Educator-Treated Mononuclear Cells Apheresis
SCE therapy circulates a patient's blood through a blood cell separator, briefly cocultures the patient's immune cells with adherent CB-SC in vitro, and returns the "educated" autologous immune cells to the patient's circulation.

No Intervention: Conventional treatment of patients with SARS-CoV-2
Patients will receive the regular treatments by only addressing their symptoms such as reducing fever and cough.



Primary Outcome Measures :
  1. Determine the number of Covid-19 patients who were unable to complete SCE Therapy [ Time Frame: 4 weeks ]
    The feasibility will be evaluated by the number of Covid-19 patients who were unable to complete SCE Therapy.


Secondary Outcome Measures :
  1. Examine the percentage of activated T cells after SCE therapy by flow cytometry [ Time Frame: 4 weeks ]
    Measurements of immune markers' changes will be preformed by flow cytometry such as activated T cells. Peripheral blood mononuclear cells (PBMC) will be collected at 1, 3, 6, 9, 12, 28 day post the SCE therapy.

  2. Assess the percentage of Th17 cells after SCE therapy by flow cytometry [ Time Frame: 4 weeks ]
    Measurements of immune marker's changes will be preformed by flow cytometry such as the percentage of Th17 cells. Peripheral blood mononuclear cells (PBMC) will be collected at 1, 3, 6, 9, 12, 28 day post the SCE therapy.

  3. Chest imaging changes by computed tomography (CT) scan of the chest [ Time Frame: 4 weeks ]
    Patients will be monitored for their chest imaging every 3 - 5 days for 4 weeks after receiving SCE therapy.

  4. Quantification of the SARS-CoV-2 viral load by real time RT-PCR [ Time Frame: 4 weeks ]
    To determine the viral load by real time RT-PCR, samples of blood, sputum, nose / throat swab will be collected from patients during the follow-up studies after receiving SCE therapy.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Adult patients (18 years)
  2. Must have a clinical diagnosis of SARS-CoV-2, with at least one of clinical symptoms (e.g., fever ≥38°C, fatigue, cough) and a positive result by the reverse-transcription polymerase chain reaction (RT-PCR) testing
  3. Patients must not have received any antiviral treatments known to affect SARS-CoV-2
  4. Patients must agree that they are not permitted to use any other treatment to affect SARS-CoV-2 during a period of 6 months after undergoing SCE therapy
  5. Adequate venous access for apheresis
  6. Ability to provide informed consent
  7. For female patients only, willingness to use FDA-recommended birth control (http://www.fda.gov/downloads/ForConsumers/ByAudience/ForWomen/FreePublications/UCM356451.pdf) until 6 months post treatment.
  8. Must agree to comply with all study requirements and be willing to complete all study visits

Exclusion Criteria:

  1. AST or ALT 2 > x upper limit of normal.
  2. Abnormal bilirubin (total bilirubin > 1.2 mg/dL, direct bilirubin > 0.4 mg/dL)
  3. Creatinine > 2.0 mg/dl.
  4. Known coronary artery disease or EKG suggestive of coronary artery disease unless cardiac clearance for apheresis is obtained from a cardiologist.
  5. Known active infection such as Hepatitis B, Hepatitis C, or Human Immunodeficiency Virus (HIV)
  6. Pregnancy assessed by a positive serum pregnancy test or breastfeeding mothers
  7. Use of immunosuppressive medication within one month of enrollment including but not limited to cyclosporine, tacrolimus, sirolimus, and chemotherapy.
  8. Anticoagulation other than ASA.
  9. Hemoglobin < 10 g/dl or platelets < 100 k/ml
  10. Is unable or unwilling to provide informed consent
  11. Presence of any other physical or psychological medical condition that, in the opinion of the investigator, would preclude participation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04299152


Contacts
Layout table for location contacts
Contact: Johnny Itticheria 6308496657 info@TianheCell.com

Sponsors and Collaborators
Tianhe Stem Cell Biotechnologies Inc.
Investigators
Layout table for investigator information
Study Director: Heng Li, MD,PhD Tianhe Stem Cell Biotechnologies Inc.

Additional Information:
Publications:

Layout table for additonal information
Responsible Party: Tianhe Stem Cell Biotechnologies Inc.
ClinicalTrials.gov Identifier: NCT04299152    
Other Study ID Numbers: 2020-TH-001
First Posted: March 6, 2020    Key Record Dates
Last Update Posted: April 14, 2020
Last Verified: April 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: Yes
Keywords provided by Tianhe Stem Cell Biotechnologies Inc.:
severe acute respiratory syndrome coronavirus
Immune modulation
Stem Cell Educator therapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Severe Acute Respiratory Syndrome
Coronavirus Infections
Pneumonia
Syndrome
Inflammation
Disease
Pathologic Processes
Lung Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Virus Diseases